精神病患者脑内胶质细胞标志物TSPO的PET研究:基于个体参与者数据的荟萃分析
该研究通过荟萃分析个体参与者数据,比较首发精神病和精神分裂症患者与健康对照的脑内TSPO水平。纳入5项研究共75例患者和77例对照,贝叶斯因子分析显示患者额叶、颞叶和海马TSPO总分布容积(VT)低于对照,提示脑免疫细胞功能或密度可能降低。
要点
- 患者额叶、颞叶和海马TSPO的VT均低于健康对照。
- 贝叶斯因子强支持患者TSPO降低而非无差异或升高。
- TSPO降低可能反映脑免疫细胞功能或密度改变。
核心结论
- 精神病患者脑内TSPO水平低于健康对照,可能对应脑免疫细胞功能或密度降低。
研究设计与样本
- 系统检索PubMed中采用第二代TSPO放射性配体比较精神病患者与健康对照的研究,并应用个体参与者数据荟萃分析。
- 共纳入5项研究,包括75例首发精神病或精神分裂症患者和77例健康对照。
主要发现
- 贝叶斯因子分析显示,在额叶、颞叶和海马,患者VT降低相对于无差异的证据强度均为BF>32。
- 患者VT降低相对于升高的证据强度均为BF>422。
- 标准化VT均值的患者-对照差值:额叶-0.48(95%可信区间-0.88至0.09),颞叶-0.47(-0.87至-0.07),海马-0.63(-1.00至-0.25)。
关键数值与推荐
- 结局指标为TSPO总分布容积(VT),测量脑区包括额叶皮层、颞叶皮层和海马。
- 采用贝叶斯因子评估患者TSPO水平升高、降低或无差异的相对支持程度。
临床怎么用
- TSPO PET可能作为精神病患者分层和治疗监测的潜在方法,但需进一步研究生物学机制及治疗相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accumulating evidence suggests that the immune system may be an important target for new treatment approaches in schizophrenia. Positron emission tomography and radioligands binding to the translocator protein (TSPO), which is expressed in glial cells in the brain including immune cells, represents a potential method for patient stratification and treatment monitoring. This study examined whether patients with first-episode psychosis and schizophrenia had altered TSPO levels compared with healthy control subjects. METHODS: PubMed was searched for studies comparing patients with psychosis with healthy control subjects using second-generation TSPO radioligands. The outcome measure was total distribution volume (VT), an index of TSPO levels, in frontal cortex, temporal cortex, and hippocampus. Bayes factors (BFs) were applied to examine the relative support for higher, lower, or no difference in patients' TSPO levels compared with healthy control subjects. RESULTS: Five studies, with 75 participants with first-episode psychosis or schizophrenia and 77 healthy control subjects, were included. BFs showed strong support for lower VT in patients relative to no difference (all BFs > 32), or relative to higher VT (all BFs > 422), in all brain regions. From the posterior distributions, mean patient-control differences in standardized VT values were -0.48 for frontal cortex (95% credible interval [CredInt] = -0.88 to 0.09), -0.47 for temporal cortex (CredInt = -0.87 to -0.07), and -0.63 for hippocampus (CredInt = -1.00 to -0.25). CONCLUSIONS: The lower levels of TSPO observed in patients may correspond to altered function or lower density of brain immune cells. Future studies should focus on investigating the underlying biological mechanisms and their relevance for treatment.
引用
- Plavén-Sigray P, Matheson GJ, Collste K, et al. Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biol Psychiatry. 2018. PMID: 29653835. doi:10.1016/j.biopsych.2018.02.1171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。